Vol.

No.

April 09, 2021Apr 09, 2021

DOWNLOAD THE PDF

Cover Story

Biden requests $6.5B to fund cancer-focused ARPA-H, an advanced research agency to be housed within NIH

By Matthew Bin Han Ong

President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.”

Editorial

The Cancer Letter gets a new website
You may have noticed that things are looking different around here

By Katie Goldberg

Lowy, Chanock, Mitchell, Von Hoff are among winners of 2021 AACR awards

Free In the Archives

Founders: Roswell Park’s Dr. Roswell Park and UCLA’s Kenneth Jonsson

Clinical Trials & Tribulations

Setting a research agenda on cannabis and cannabinoids: Updates from the NCI symposium

By Dylan M. Zylla

In Brief

Deborah Schrag named chair of the Department of Medicine at Memorial Sloan Kettering

Carolyn Starrett named CEO of Flatiron Health

Brian Bolwell named chair of physician leadership and development at Cleveland Clinic

California Senate passes Cancer Patients Bill of Rights

Elizabeth Herbert named VP for Network Services at Smilow Cancer Hospital

Harvard Medical School receives $9M for rare cancer research

University of Kansas Cancer Center receives $4.2M from NCI to research breast cancer chemoprevention

Thomas J. Kelly Jr. named associate director for cancer research training and education at UAMS

Rollins gift to establish urgent care center for Winship cancer patients

UAMS Winthrop P. Rockefeller Cancer Institute establishes Breast Center

Physicians from Texas Colon & Rectal Specialists join the The US Oncology Network

ASCO oncology summer internship program aims to increase diversity in oncology workforce

City of Hope, Hospital Israelita Albert Einstein sign agreement to advance cancer care in Latin America

Pascale Foundation joins Caris Life Sciences’ Precision Oncology Alliance

Funding Opportunities

DoD Breast Cancer Research Program anticipated funding opportunities for FY21

DoD Prostate Cancer Research Program anticipated funding opportunities for FY21

Clinical Roundup

Study revises understanding of cancer metabolism

Resistance to immunotherapy urothelial bladder cancer patients traced to specific sets of immune cells

Drugs & Targets

Sacituzumab govitecan receives FDA approval for TNBC

FDA approves new dosing regimen for cetuximab

NCCN recognizes Oncotype DX test as the only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

TriSalus Life Sciences, MD Anderson collaboration to evaluate treatment of solid tumors

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 34 - September 18, 2026